PL2142570T3 - Przeciwciała skierowane przeciw EPCAM i ich zastosowania - Google Patents

Przeciwciała skierowane przeciw EPCAM i ich zastosowania

Info

Publication number
PL2142570T3
PL2142570T3 PL08759374T PL08759374T PL2142570T3 PL 2142570 T3 PL2142570 T3 PL 2142570T3 PL 08759374 T PL08759374 T PL 08759374T PL 08759374 T PL08759374 T PL 08759374T PL 2142570 T3 PL2142570 T3 PL 2142570T3
Authority
PL
Poland
Prior art keywords
epcam antibody
therapeutic
designated
high affinity
shows high
Prior art date
Application number
PL08759374T
Other languages
English (en)
Polish (pl)
Inventor
Anna Maria Anastasi
Fiorella Petronzelli
Santis Rita De
Saverio Alberti
Original Assignee
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma Spa filed Critical Alfasigma Spa
Publication of PL2142570T3 publication Critical patent/PL2142570T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL08759374T 2007-04-04 2008-04-02 Przeciwciała skierowane przeciw EPCAM i ich zastosowania PL2142570T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07105628 2007-04-04
PCT/EP2008/053913 WO2008122551A2 (en) 2007-04-04 2008-04-02 Anti-epcam antibody and uses thereof
EP08759374A EP2142570B1 (en) 2007-04-04 2008-04-02 Anti-epcam antibody and uses thereof

Publications (1)

Publication Number Publication Date
PL2142570T3 true PL2142570T3 (pl) 2011-11-30

Family

ID=38458122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08759374T PL2142570T3 (pl) 2007-04-04 2008-04-02 Przeciwciała skierowane przeciw EPCAM i ich zastosowania

Country Status (21)

Country Link
US (1) US8318911B2 (enExample)
EP (1) EP2142570B1 (enExample)
JP (1) JP5631733B2 (enExample)
KR (1) KR101683884B1 (enExample)
CN (1) CN101970497B (enExample)
AT (1) ATE512988T1 (enExample)
AU (1) AU2008235566B2 (enExample)
BR (1) BRPI0810096A8 (enExample)
CA (1) CA2682296C (enExample)
CY (1) CY1111819T1 (enExample)
DK (1) DK2142570T3 (enExample)
EA (1) EA023679B1 (enExample)
ES (1) ES2367675T3 (enExample)
HR (1) HRP20110620T1 (enExample)
IL (1) IL201196A0 (enExample)
MX (1) MX2009010444A (enExample)
PL (1) PL2142570T3 (enExample)
PT (1) PT2142570E (enExample)
RS (1) RS52040B (enExample)
SI (1) SI2142570T1 (enExample)
WO (1) WO2008122551A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2474822A1 (en) 2003-01-24 2012-07-11 University of Utah Methods of predicting mortality risk by determining telomere length
CA2748265C (en) 2008-12-22 2018-04-03 University Of Utah Research Foundation Monochrome multiplex quantitative pcr
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
EP2710042A2 (en) * 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
WO2013003624A2 (en) 2011-06-29 2013-01-03 Academia Sinica The capture, purification and release of biological substance using a surface coating
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
US9494500B2 (en) 2012-10-29 2016-11-15 Academia Sinica Collection and concentration system for biologic substance of interest and use thereof
EP2999800B1 (en) 2013-05-22 2019-09-25 Telomere Diagnostics Inc. Measures of short telomere abundance
EP3126814B1 (en) 2014-04-01 2019-06-12 Academia Sinica Methods and systems for cancer diagnosis and prognosis
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
CA2971169A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
WO2017023704A1 (en) * 2015-07-31 2017-02-09 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
KR20190038567A (ko) 2016-07-26 2019-04-08 테사 테라퓨틱스 피티이. 엘티디. 키메라 항원 수용체
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
WO2020216210A1 (zh) * 2019-04-22 2020-10-29 江苏恒瑞医药股份有限公司 抗EpCAM抗体及其应用
AU2020292304B2 (en) * 2019-06-11 2023-03-30 Bioatla, Inc. Conditionally active anti-EpCam antibodies, antibody fragments, their immunoconjugates and uses thereof
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN112094350B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体
EP4190808A4 (en) * 2020-08-19 2024-07-31 Suzhou Immunofoco Biotechnology Co., Ltd. Humanized antibody, chimeric antigen receptor, nucleic acid, vector, cell and use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5578287A (en) 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
JP3427871B2 (ja) 1996-06-24 2003-07-22 戸田工業株式会社 コバルト被着型針状磁性酸化鉄粒子粉末
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
US7435804B2 (en) * 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b

Also Published As

Publication number Publication date
CN101970497A (zh) 2011-02-09
RS52040B (sr) 2012-04-30
IL201196A0 (en) 2010-05-17
EP2142570B1 (en) 2011-06-15
WO2008122551A3 (en) 2008-12-04
ATE512988T1 (de) 2011-07-15
AU2008235566A1 (en) 2008-10-16
MX2009010444A (es) 2009-10-20
SI2142570T1 (sl) 2012-01-31
JP5631733B2 (ja) 2014-11-26
EA200970923A1 (ru) 2010-04-30
KR101683884B1 (ko) 2016-12-07
BRPI0810096A2 (pt) 2014-10-21
PT2142570E (pt) 2011-09-13
WO2008122551A2 (en) 2008-10-16
US20100092491A1 (en) 2010-04-15
CN101970497B (zh) 2017-05-10
ES2367675T3 (es) 2011-11-07
CA2682296C (en) 2017-02-28
EP2142570A2 (en) 2010-01-13
BRPI0810096A8 (pt) 2017-12-26
CA2682296A1 (en) 2008-10-16
JP2010523096A (ja) 2010-07-15
CY1111819T1 (el) 2015-10-07
DK2142570T3 (da) 2011-10-03
AU2008235566B2 (en) 2013-06-06
KR20100016237A (ko) 2010-02-12
EA023679B1 (ru) 2016-06-30
WO2008122551A9 (en) 2009-02-05
HRP20110620T1 (hr) 2011-09-30
US8318911B2 (en) 2012-11-27

Similar Documents

Publication Publication Date Title
IL201196A0 (en) Anti-epcam antibody and uses thereof
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
PH12019500600A1 (en) Antibodies against signal-regulatory protein alpha and methods of use
MX2024015039A (es) Composiciones anti-cd24 y usos de las mismas
TW200510459A (en) RG1 antibodies and uses thereof
WO2019224716A8 (en) Antibodies specific for gucy2c and uses thereof
UA113712C2 (xx) Антитіло до fap і способи його застосування
TW200732349A (en) Anti-OX40L antibodies and methods using same
EP4364754A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
EP4434543A3 (en) Human igg1 fc region variants and uses thereof
NZ600143A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
WO2016210365A3 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
EP4527466A3 (en) Anti-dll3 chimeric antigen receptors and uses thereof
IL214325A (en) Antibody against cmet, a drug that includes and uses it
WO2018183182A8 (en) Methods and compositions for reduction of immunogenicity
EP2402373A3 (en) Anti-EphB4 Antibodies and Methods Using Same
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
EP4512830A3 (en) Antibodies useful in cancer diagnosis
WO2017015634A3 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
WO2010034825A3 (en) Novel antibodies recognizing native annexin a3
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.